Data Foundry

Drug recalls 2017

Paroxetine Extended-Release Tablets USP — Class III drug recall D-0974-2017

Terminated recall by Lupin Pharmaceuticals Inc., reported 2017-07-19, distributed nationwide. Failed Dissolution Specifications: out of specification observed in dissolution testing at 3 month long term s

Recall numberD-0974-2017
Product typeDrug
ClassificationClass III
StatusTerminated
Voluntary or mandatedVoluntary
Recalling firmLupin Pharmaceuticals Inc., Baltimore, MD, United States
Recall initiated2017-06-22
Classified2017-07-12
Reported by FDA2017-07-19
Terminated2019-01-17
DistributedNationwide (US)
Quantity12,480 bottles
Reason classesspecification failure
NDC68180-0645, 68180-0645-01, 68180-0645-02, 68180-0645-06, 68180-0646, 68180-0646-01, 68180-0646-02, 68180-0646-03, 68180-0646-06, 68180-0647, 68180-0647-01, 68180-0647-02, 68180-0647-03, 68180-0647-06
Lot numbersH605710, H605711, H605712, H702202, H702255
Expiration dates2018-11-20, 2019-03-20

Product

Paroxetine Extended-Release Tablets USP, 12.5 mg, 30 count bottle, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland, 21202, Manufactured by: Lupin Limited, Pithampur (M.P.) 454 775, India, NDC: 68180-647-06

Reason for recall

Failed Dissolution Specifications: out of specification observed in dissolution testing at 3 month long term stability study.

Machine access

This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0974-2017. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.

Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.